Skip to main content
Divisions Faculty Pharmacoengineering and Molecular Pharmaceutics,
Grayson Mendenhall
May 14, 2015



Michael Jay
Michael Jay, PhD

Michael Jay, PhD, has been named executive vice dean at the UNC Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill. Jay will serve as the School’s chief academic officer.

Jay is a Fred Eshelman Distinguished Professor in the Division of Molecular Pharmaceutics at the School and has been the division’s chair since 2012. Eshelman Professor Leaf Huang, PhD, who previously chaired the division from 2005 to 2012, will serve as interim chair of MOPH while the School searches for a permanent replacement for Jay.

Jay joined the UNC Eshelman School of Pharmacy in 2008 after a twenty-seven-year at the University of Kentucky College of Pharmacy. At UK he rose through the academic ranks to become professor of pharmaceutics and a professor of radiology in the UK College of Medicine. He also served as the director of graduate studies from 1992 to 1998 and director of the Center for Pharmaceutical Science and Technology from 1998 to 2007.

In 1980 Jay received his PhD in pharmaceutical sciences from the UK College of Pharmacy. He served as an assistant professor of nuclear medicine at the University of Connecticut Health Center from 1980 to 1981 and then returned to UK as an assistant professor of medicinal chemistry in 1981.

Jay has received a number of awards, including the Berson-Yalow Award from the Society of Nuclear Medicine, the Mendell Award for Scientific Excellence in Pharmaceutical Sciences, and the Excellence in Pharmaceutical Graduate Education Award from the Department of Pharmaceutical Sciences at the University of Kentucky. The first-year doctor of pharmacy class selected Jay as their instructor of the year in 2014 and 2015. He is the author of approximately 130 peer-reviewed articles.

Jay is also a fellow of the American Association of Pharmaceutical Scientists and the cofounder of Arcato Laboratories, Inc. and Capture Pharmaceuticals, Inc.

Latest News


Comments are closed.